Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with structural similarity to human GLP-1. This peptide has been extensively studied for its effects on glucose metabolism, appetite regulation, and body weight management.

The peptide works by binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. In the brain, it acts on appetite centers to reduce food intake. In the GI tract, it slows gastric emptying, contributing to increased satiety.

Semaglutide has a modified structure that provides resistance to DPP-4 enzyme degradation, resulting in a significantly longer half-life than native GLP-1. This allows for less frequent dosing and more sustained therapeutic effects.

Clinical trials have demonstrated significant effects on body weight, with participants experiencing substantial reductions over extended treatment periods. The peptide has also shown benefits for cardiovascular health markers and metabolic parameters.